New drug application submitted to FDA for umbralisib as a treatment for patients with previously treated marginal zone lymphoma (MZL) or follicular lymphoma (FL)

In the study of this investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, the primary endpoint of overall response rate (40-50%) was met for all treated MZL patients (n=69) and FL patients (n=118).


Biospace Inc.